SCHEMBL652066

SCHEMBL652066

Cc1ccc(N=C2NC(=O)C(=Cc3cnc(NCCN4CCCC4)s3)S2)c(C)c1

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 11/20 0.51
NPSR1 Q6W5P4 6/20 0.51
TDP1 Q9NUW8 3/20 0.51
MAPK1 P28482 3/20 0.51
L3MBTL1 Q9Y468 2/20 0.51
RECQL P46063 1/20 0.51
POLB P06746 1/20 0.49
HPGD P15428 1/20 0.49
LMNA P02545 4/20 0.47
RNASEL Q05823 1/20 0.40
KMT2A Q03164 8/20 0.39
MEN1 O00255 7/20 0.39
MITF O75030 1/20 0.37
NPC1 O15118 2/20 0.37
ALDH1A1 P00352 2/20 0.37
ALOX15 P16050 1/20 0.36
PTGS2 P35354 1/20 0.36
RAB9A P51151 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10227933 1.00 MAPT (0.51) MAPTNPSR1TDP1MAPK1L3MBTL1
SCHEMBL653415 0.95 MAPT (0.50) MAPTNPSR1TDP1MAPK1L3MBTL1
SCHEMBL10226368 0.95 MAPT (0.50) MAPTNPSR1TDP1MAPK1L3MBTL1
SCHEMBL650930 0.88 MAPT (0.48) MAPTNPSR1TDP1MAPK1L3MBTL1
SCHEMBL650929 0.88 MAPT (0.48) MAPTNPSR1TDP1MAPK1L3MBTL1
SCHEMBL10176363 0.87 MAPT (0.41) MAPTNPSR1TDP1MAPK1L3MBTL1
SCHEMBL652065 0.85 MAPT (0.47) MAPTNPSR1TDP1MAPK1L3MBTL1
SCHEMBL651556 0.84 MAPT (0.53) MAPTNPSR1TDP1MAPK1L3MBTL1
SCHEMBL651555 0.84 MAPT (0.53) MAPTNPSR1TDP1MAPK1L3MBTL1
SCHEMBL12383002 0.84 MAPT (0.50) MAPTNPSR1TDP1MAPK1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2423204-A1 THIAZOLIDINONE DERIVATIVE SBI Biotech Co., Ltd. (JP) 2012-02-29 EP disclosed
US-8119812-B2 Thiazolidinone derivative SBI BIOTECH CO., LTD. (JP) 2012-02-21 US disclosed
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE SBI BIOTECH CO., LTD. (JP) 2011-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE CDC7, CDK17, CDCA2 MAPT 3657/4885NPSR1 4464/4885TDP1 1880/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.